Search Results for keywords:"federal food drug and cosmetic act"

Search Results: keywords:"federal food drug and cosmetic act"

S. 5046 — An Act To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.
December 12, 2024
Status:Engrossed in Senate
Congress:118
Words:804
S. 5046, also known as the “FDA Modernization Act 3.0,” is a bill that requires the Secretary of Health and Human Services, through the Commissioner of Food and Drugs, to issue new regulations about nonclinical testing methods. This legislation mandates an interim final rule...
Simple Explanation
The FDA Modernization Act 3.0 is a new law that asks for rules to be made so that scientists can use new ways instead of animal testing to check if medicines are safe, but it might be confusing and cost money without telling everyone how much.
S. 4827 — To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration.
💰
July 29, 2024
Status:Introduced in Senate
Congress:118
Words:2,134
S. 4827, also known as the "Dietary Supplement Listing Act of 2024," aims to increase transparency and accessibility to information about dietary supplements. The bill would require all dietary supplement manufacturers to list their products with the Food and Drug...
Simple Explanation
S. 4827 is a new rule that says companies making vitamins and supplements have to tell the FDA what's in their products, and everyone will be able to look this up on a big list online. This rule also sets aside money to help create this list and make sure it's safe and easy for people to use.
H. R. 10406 — To amend the Federal Food, Drug, and Cosmetic Act to authorize requiring the manufacturers of a covered device to disclose to a patient all patient-specific data that is recorded or transmitted by the device and accessible to the manufacturer, and for other purposes.
December 12, 2024
Status:Introduced in House
Congress:118
Words:1,227
The Patient Device Data Access Act of 2024 amends the Federal Food, Drug, and Cosmetic Act to allow patients to access all data recorded or transmitted by medical devices they use, which is accessible to the manufacturers. The bill requires manufacturers to share this data in...
Simple Explanation
The Patient Device Data Access Act of 2024 wants to make sure that people who use certain medical devices can see all the information their device collects about them, just like their device's manufacturers can. It helps patients know more about their devices, if there's a problem with it, and how to get their information in a way they can understand.
S. 4878 — To amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.
July 31, 2024
Status:Introduced in Senate
Congress:118
Words:1,115
S. 4878, known as the "Reforming Evergreening and Manipulation that Extends Drug Years Act" or the "REMEDY Act," aims to change how new drug applications are approved under the Federal Food, Drug, and Cosmetic Act. The bill introduces the concept of a "covered patent," requiring drug...
Simple Explanation
The REMEDY Act is a new rule to stop drug makers from using too many patents to keep their medicine special for longer, which could make it harder for other companies to make the same medicine. It says each drug maker can only pick one special patent that gets a little extra time before others can make the same drug.
H. R. 3433 — An Act To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
September 24, 2024
Status:Referred in Senate
Congress:118
Words:4,770
H. R. 3433, titled the "Give Kids a Chance Act of 2024," aims to amend the Federal Food, Drug, and Cosmetic Act to improve research and regulation of molecularly targeted pediatric cancer drugs. The bill includes measures to prioritize research on pediatric drug uses, ensure the completion of...
Simple Explanation
H. R. 3433 wants to help doctors find better treatments for kids with cancer, by making sure medicines are safe for them and making it easier to work with people from other countries.
S. 4918 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the personal importation of safe and affordable drugs from approved pharmacies in Canada.
July 31, 2024
Status:Introduced in Senate
Congress:118
Words:1,085
S. 4918 proposes changes to the Federal Food, Drug, and Cosmetic Act to allow individuals in the U.S. to import certain prescription drugs from approved Canadian pharmacies for personal use. The drugs must be purchased from a licensed Canadian pharmacy, dispensed by a...
Simple Explanation
In a plan called S. 4918, people in the U.S. might be able to buy some medicines from Canada if it's safe and from special, approved stores, but not things like special drugs or shots.
H. R. 7248 — To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.
February 06, 2024
Status:Introduced in House
Congress:118
Words:2,101
H.R. 7248, also known as the “FDA Modernization Act 3.0,” aims to amend the Federal Food, Drug, and Cosmetic Act to improve nonclinical testing methods for drugs. The bill's goal is to establish a process for qualifying nonclinical testing methods that reduce or replace the...
Simple Explanation
H.R. 7248 is like a plan to find better ways to test if medicine is safe without using so many animals, making the process quicker and better for everyone.
S. 4426 — To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
May 23, 2024
Status:Introduced in Senate
Congress:118
Words:5,340
The bill S. 4426, known as the "Promising Pathway Act 2.0," proposes changes to the Federal Food, Drug, and Cosmetic Act. It introduces a temporary conditional approval pathway for certain drugs and biological products that treat rare, progressive, or serious diseases. This...
Simple Explanation
The Promising Pathway Act 2.0 is a plan to let some important new medicines for serious diseases become available to people sooner, even though doctors and scientists are still studying them. However, it also wants to make sure that these medicines are safe by making medicine makers check how well they work and keep patients informed.

Showing 1 to 8 of 8 results